Combined neutrophil-to-lymphocyte ratio predicts progression-free survival in metastatic cervical cancer patients treated with immune checkpoint inhibitors.
A Simple Blood Test May Predict Cervical Cancer Treatment Success
This retrospective cohort analysis evaluated 148 individuals with metastatic or recurrent cervical cancer treated with immune checkpoint inh…
A simple blood test ratio may predict who responds best to immunotherapy for advanced cervical cancer, helping doctors tailor treatment with…
Pembrolizumab ranks highest for survival in cervical cancer network meta-analysis
Review finds pembrolizumab may improve survival in advanced cervical cancer
A Bayesian network meta-analysis of phase 3 RCTs compared immune checkpoint inhibitors in locally advanced and metastatic cervical cancer. P…
Adding pembrolizumab to standard treatment for advanced cervical cancer is linked to better survival and longer time before the disease prog…